• A plain language summary of the results from the phase 2b HERIZON-BTC-01 study of zanidatamab in participants with HER2-amplified biliary tract cancer
• Adverse Events of PD-1, PD-L1, CTLA-4, and LAG-3 Immune Checkpoint Inhibitors: An Analysis of the FDA Adverse Events Database
• AGR2: The Covert Driver and New Dawn of Hepatobiliary and Pancreatic Cancer Treatment
• Antibody-drug conjugates for hepato-pancreato-biliary malignancies: "Magic bullets" to the rescue?
• Artificial intelligence-powered spatial analysis of tumor-infiltrating lymphocytes as a predictive biomarker for immune checkpoint inhibitors in biliary tract cancer
• Atrazine promotes cholangiocarcinoma cell proliferation and migration via GPER-mediated PI3K/Akt/NF-κB pathway
• Bevacizumab Erlotinib Switch Maintenance in Chemo-Responsive Advanced Gallbladder and Cholangiocarcinoma (BEER BTC): A Multicenter, Open-Label, Randomized, Phase II Trial
• Causal relationship between immune cell phenotypes and risk of biliary tract cancer: evidence from Mendelian randomization analysis
• Characterization of a Syngeneic Orthotopic Model of Cholangiocarcinoma by [¹⁸F]FDG-PET/MRI
• Cholangioscopy-guided laser ablation for intraductal papillary neoplasm of bile duct
• CircEZH2 promotes gallbladder cancer progression and lipid metabolism reprogramming through the miR-556-5p/SCD1 axis
• Clinical outcomes and risk stratification in unresectable biliary tract cancers undergoing radiation therapy
• Clinicopathological Study of Resected and Recurrent Cases of Intrahepatic Intraductal Papillary Neoplasm of the Bile Duct
• Comparative Cost-Effectiveness of Gemcitabine and Cisplatin in Combination with S-1, Durvalumab, or Pembrolizumab as First-Line Triple Treatment for Advanced Biliary Tract Cancer
• Comparison of the Size Measurement of Gallbladder Polyps by Three Different Radiologists in Abdominal Ultrasonography
• Correction: Comparison of proton-based Definitive chemoradiotherapy and surgery-based therapy for esophageal squamous cell carcinoma: a multi-center retrospective Japanese cohort study
• Delayed-onset biliary peritonitis after endoscopic ultrasound-guided hepaticogastrostomy for malignant distal biliary obstruction
• Design of the distribution of iron oxide (Fe₃O₄) nano-particle drug in realistic cholangiocarcinoma model and the simulation of temperature increase during magnetic induction hyperthermia
• Development of a subunit vaccine against the cholangiocarcinoma causing <em>Opisthorchis viverrini</em>: a computational approach
• Does the size of the neuroendocrine-carcinoma component determine the prognosis of gallbladder cancer?
• Duodenal Fluid Analysis as a Rewarding Approach to Detect Low-Abundance Mutations in Biliopancreatic Cancers
• Effect of bile duct resection on the prognosis of patients with hepatocellular carcinoma combined with extrahepatic bile duct tumor thrombus
• Efficacy and safety of camrelizumab, apatinib, and capecitabine combination therapy in advanced biliary tract cancer: a phase 2, nonrandomized, prospective study
• Efficacy and safety of maintenance therapy with anlotinib for advanced cholangiocarcinoma after first-line chemotherapy and the variations in efficacy based on different neutrophil-to-lymphocyte ratio (NLR)
• Emerging biomarkers for immunotherapy response in biliary tract cancers: a comprehensive review of immune checkpoint inhibitor strategies
• Emerging Therapies for the Management of Human Epidermal Growth Factor Receptor 2-/ERBB2-Altered Advanced Biliary Tract Cancers
• Endoscopic vacuum therapy (eVAC) combined with continuous perianastomotic irrigation for prevention of anastomotic leak after surgical ampullectomy
• Erdafitinib in Asian patients with advanced solid tumors: an open-label, single-arm, phase IIa trial
• Expression and molecular insights of lima1 in cholangiocarcinoma
• FDX1 downregulation activates mitophagy and the PI3K/AKT signaling pathway to promote hepatocellular carcinoma progression by inducing ROS production
• Focusing on the Immune Cells: Recent Advances in Immunotherapy for Biliary Tract Cancer
• Generation of a biliary tract cancer cell line atlas reveals molecular subtypes and therapeutic targets
• HDR brachytherapy versus robotic-based and linac-based stereotactic ablative body radiotherapy in the treatment of liver metastases - A dosimetric comparison study of three radioablative techniques
• Hepatic Inflammatory Pseudotumor Mimicking Cholangiocarcinoma: A Rare Case and Literature Review
• How to improve pre-operative diagnostics of pancreatobiliary lesions? From immunohistochemistry to Next Generation Sequencing
• Huaier inhibits cholangiocarcinoma cells through the twist1/FBP1/Wnt/β-catenin axis
• Human Hepatobiliary Organoids: Recent Advances in Drug Toxicity Verification and Drug Screening
• Identification and validation of inflammatory subtypes in intrahepatic cholangiocellular carcinoma
• Identification of PANoptosis-relevant subgroups and predicting signature to evaluate the prognosis and immune landscape of patients with biliary tract cancer
• Imaging of Biliary Tree Abnormalities
• Impact of osteopenia and osteosarcopenia on the outcomes after surgery of hepatobiliary-pancreatic cancers
• Improved Survival With Chemotherapy in Patients With Malignant Biliary Tract Obstruction After Percutaneous Transhepatic Biliary Drainage (PTBD)
• Integrating Molecular Insights into Biliary Tract Cancer Management: A Review of Personalized Therapeutic Strategies
• Intra-arterial PSMA injection using hepatic arterial infusion pump in intrahepatic cholangiocarcinoma: a proof-of-concept study
• Is cross-species horizontal gene transfer responsible for gallbladder carcinogenesis
• Is the Prognostic Nutritional Index a Novel Prognostic Factor in Patients With Unresectable/Metastatic Gallbladder and Cholangiocarcinoma Receiving Chemotherapy?
• Knockdown of long noncoding RNA AL161431.1 inhibits malignant progression of cholangiocarcinoma
• Liver and bile duct organoids and tumoroids
• Liver Oligometastasis in Biliary Tract Cancer and Impact on Survival Outcomes
• Long-term hepatobiliary disorder associated with trastuzumab emtansine pharmacovigilance study using the FDA Adverse Event Reporting System database
• Long-Term Risks of Benign and Malign Complications after Endoscopic Sphincterotomy in the Management of Benign Biliopancreatic Pathology: A Cohort Study
• Management of iatrogenic perforations during endoscopic interventions in the hepato-pancreatico-biliary tract
• Misdiagnosis Based on Neoplastic Markers-Extremely High Alpha-Fetoprotein in Patients with Intrahepatic Cholangiocarcinoma with Literature Review of the Published Cases
• Molecular Differences With Therapeutic Implications in Early-Onset Compared With Average-Onset Biliary Tract Cancers
• Multicellular 3D bioprinted human gallbladder carcinoma for<em>in vitro</em>mimicry of tumor microenvironment and intratumoral heterogeneity
• Multiplexed immunohistochemical analysis of the immune microenvironment of biliary tract cancers pre- & post-neoadjuvant chemotherapy: case series
• Nanofiber-based delivery of evodiamine impedes malignant properties of intrahepatic cholangiocarcinoma cells by targeting HDAC4 and restoring TPM1 transcription
• Network meta-analysis of adjuvant chemotherapy in biliary tract cancers: Setting the scene for new randomized evidence
• Neuroendocrine carcinoma of the gallbladder: A case report and literature review
• Optimizing adjuvant treatment strategies for non-pancreatic periampullary cancers
• Pan-lysyl oxidase inhibition disrupts fibroinflammatory tumor stroma, rendering cholangiocarcinoma susceptible to chemotherapy
• PARP inhibitor therapy in patients with IDH1 mutated cholangiocarcinoma
• Pathologic and Molecular Features of Perihilar Cholangiocarcinoma Based on U-P Point Division
• Percutaneous endobiliary radiofrequency ablation and stent placement for unresectable malignant biliary obstruction: a propensity score matching retrospective study
• Percutaneous transhepatic cholangioscopy combined with endoscopic retrograde cholangiopancreatography for bilateral biliary bridge drainage for malignant biliary obstruction
• Phase II Placebo-Controlled Study of the Effect and Safety of Nanvuranlat in Patients with Advanced Biliary Tract Cancers Previously Treated by Systemic Chemotherapy
• Pitfalls of cytological diagnosis of tumours of the pancreaticobiliary tract
• PIWI-interacting RNAs (PiRNAs) as emerging biomarkers and therapeutic targets in biliary tract cancers: A comprehensive review
• Postoperative distress and influencing factors in patients with pancreatobiliary cancer
• Potential of Anti-Leukotriene Drugs as New Therapeutic Agents for Inhibiting Cholangiocarcinoma Progression
• Predicting lymph node metastasis using preoperative parameters in patients with T1 ampulla of vater cancer
• Preliminary clinical use of hepatic arterial infusion chemotherapy combined with lenvatinib and tislelizumab in the treatment of unresectable intrahepatic cholangiocarcinoma
• Preliminary response to Tislelizumab plus chemotherapy drugs in patient with periampullary carcinoma: a report of one case and a literature review
• Prognostic evaluation in gallbladder carcinoma: Introducing a composite risk model integrating nutritional and immune markers
• Prognostic factors in patients with intrahepatic cholangiocarcinoma
• Prognostic impact of combination therapy with gemcitabine and cisplatin plus S-1 and subsequent conversion surgery for initially unresectable upper biliary tract cancers
• Prognostic Impact of Neoadjuvant Chemotherapy in Localized or Locoregionally Advanced Gallbladder Cancer: A Population-Based and Propensity Score Matched SEER Analysis
• PTBP3 Mediates IL-18 Exon Skipping to Promote Immune Escape in Gallbladder Cancer
• PUM1-TRAF3 fusion protein activates non-canonical NF-kappaB signaling via rescued NIK in biliary tract cancer
• Radiofrequency ablation via catheter and transpapillary access in patients with cholangiocarcinoma (ACTICCA-2 trial) - a multicenter, randomized, controlled, open-label investigator-initiated trial
• Ramucirumab in second-line advanced colorectal cancer therapy: A study on therapeutic outcomes and hepatic sinusoidal platelet aggregation
• Real-world treatment patterns, resource utilization and costs in biliary tract cancers in the USA
• Recent Advances in Immunotherapy for Advanced Biliary Tract Cancer
• Response to the letter by Buldukoglu et al. regarding our manuscript "Body mass index and survival among patients with advanced biliary tract cancer: a single-institutional study with nationwide data-based validation"
• Role of (64)CuCl(2) PET/CT in Detecting and Staging Muscle-Invasive Bladder Cancer: Comparison with Contrast-Enhanced CT and (18)F-FDG PET/CT
• Role of Gut Microbial Metabolites in the Pathogenesis of Primary Liver Cancers
• Small duct and large duct type intrahepatic cholangiocarcinoma reveal distinct patterns of immune signatures
• Spatial multiomics reveals a subpopulation of fibroblasts associated with cancer stemness in human hepatocellular carcinoma
• Spatial transcriptomics profiling of gallbladder adenocarcinoma: a detailed two-case study of progression from precursor lesions to cancer
• Strategies for treating the cold tumors of cholangiocarcinoma: core concepts and future directions
• Synchronous primary multiple cancer: distal cholangiocarcinoma of the intrapancreatic common bile duct and intraductal papillary mucinous tumor associated with ductal adenocarcinoma of the pancreatic tail
• Targeted therapies in advanced biliary malignancies: a clinical review
• The effectiveness of adequate lymphadenectomy in radically-resected cases with pathologically-confirmed node-negative biliary tract cancers: A SEER-based retrospective cohort study
• The role of immune checkpoint inhibitors in the first-line treatment for patients with advanced biliary tract cancer: a systematic review and meta-analysis of randomized trials
• The role of marital status in gallbladder cancer: a real-world competing risk analysis
• The Search for Risk, Diagnostic and Prognostic Biomarkers of Cholangiocarcinoma and their Biological and Clinicopathological Significance
• The Search for Risk, Diagnostic, and Prognostic Biomarkers of Cholangiocarcinoma and Their Biological and Clinicopathologic Significance
• Transcriptomic profiling of intermediate cell carcinoma of the liver
• Trastuzumab Deruxtecan in Human Epidermal Growth Factor Receptor 2-Expressing Biliary Tract Cancer (HERB; NCCH1805): A Multicenter, Single-Arm, Phase II Trial
• Unveiling the unprecedented - Very late brain metastasis in cholangiocarcinoma: A case report and comprehensive analysis